This website is intended for healthcare professionals only

Trending Topic

Ankylosing Spondylitis
7 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

At the American College of Rheumatology (ACR) Convergence 2025, Dr. Pamela Weiss delivered a focused presentation on the diagnosis and management of axial juvenile spondyloarthritis (axJSpA), highlighting key distinctions and overlaps with adult-onset disease. This targeted article synthesizes the principal objectives and takeaways from that session: identification of the characteristic clinical features of axJSpA, the […]

Sjogren’s Disease

An Introduction to Sjogren’s Disease

Mark CompleteCompleted
BookmarkBookmarked

With numerous national and international meetings taking place throughout the year, choosing which conferences to attend can be difficult. While scientific programs remain a major draw, opportunities for networking, collaboration, career development and presenting research are often just as valuable. To help identify the meetings making the biggest impact across rheumatology, we asked members of the touchIMMUNOLOGY community to share the conferences they're prioritizing this year and what makes them worth attending.

Physician burnout
touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

RMDs: Experts tell you what to expect in 2025
Mark CompleteCompleted
BookmarkBookmarked

To gain expert insight into the most impactful developments of the past year and the trends set to shape the next, we reached out to our esteemed expert faculty. From advances in targeted therapies to the integration of AI and steps towards precision medicine, here’s what our experts had to say.

35 mins
Sponsored Content
touchEXPERT BRIEFING
For HCPs in: Global, excluding UK

Watch leading experts discuss updates in the treatment of systemic lupus erythematosus (SLE), lupus nephritis (LN) and Sjögren’s disease, based on data presented at EULAR 2024.

Mark CompleteCompleted
BookmarkBookmarked

As we have come to expect, EULAR 2024 was a busy and productive meeting, packed with news and lively discussions among rheumatologists. The conference, which took place in Vienna, Austria, highlighted a wealth of innovative research and significant advancements in rheumatology. ...

Developed by Touch
Coverage from: EULAR Highlights

touchIMMUNOLOGY spoke with editorial board member Alessia Alunno (University of L'Aquila, Italy) to discuss her highlights from the European Alliance of Associations for Rheumatology (EULAR) annual meeting in the field of Sjögren’s syndrome, and summarize the main take-home ...

Coverage from: EULAR Highlights

It was great to talk with Professor Xavier Mariette (Université Paris-Saclay and Hôpital Bicêtre, Paris, France) around the current challenges and potential advances in treating Sjögren’s syndrome. Questions Why have so many clinical trials failed in ...

Coverage from: EULAR Highlights

It was a delight to catch up with Professor Xavier Mariette (Université Paris-Saclay and Hôpital Bicêtre, Paris, France) around the phase 2 study investigating subcutaneous belimumab and intravenous rituximab in primary Sjögren’s syndrome. The abstract 'SAFETY AND ...

Load More...
Close Popup